Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.
Caron Jacobson, MD, a senior physician and medical director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.
The introduction of CD19-targeted CAR T-cell therapy has transformed the treatment of patients with CD19-positive cancers, says Jacobson, adding that the effects of CAR T-cell therapy have been felt across hematologic malignancies.
As these products continue in development, research efforts are seeking ways to apply this technology to other diseases that do not express CD19, Jacobson explains.
With a number of ongoing clinical trials underway, the field is hopeful that these products will receive new regulatory indications so that the benefits observed in B-cell malignancies can translate to other tumor types, Jacobson concludes.